Author:
Pradier Melanie F.,Reis Bernhard,Jukofsky Lori,Milletti Francesca,Ohtomo Toshihiko,Perez-Cruz Fernando,Puig Oscar
Funder
ADVENTURE
MLPM2012
Comunidad de Madrid
Harvard Data Science Initiative
Center for Research on Computation and Society, Harvard University
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference17 articles.
1. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009;34:649–56.
2. Capurro MI, Xiang Y, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245–55.
3. Sun CK, Chua M-S, He J, So Samuel K. Suppression of Glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia. 2011;13:735–IN25.
4. Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832–8.
5. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009;378:279–84.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献